RTA 408 Capsules in Patients With Mitochondrial Myopathy – MOTOR

Overview

Mitochondrial myopathies are a multisystemic group of disorders that are characterized by a wide range of biochemical and genetic mitochondrial defects and variable modes of inheritance. Currently there are no effective treatments for this disease. Despite the heterogeneous myopathy phenotypes, a unifying feature of mitochondrial myopathies is that the pathogenic mtDNA mutations and/or nuclear mutations of the electron transport chain invariably lead to dysfunctional mitochondrial respiration. This reduction in mitochondrial respiration leads to a reduced ability to produce cellular adenosine triphosphate (ATP), often resulting in muscle weakness, exercise intolerance, and fatigue in patients with mitochondrial myopathies.

RTA 408 is a potent activator of Nrf2 and inhibitor of NF κB (nuclear factor kappa-light-chain-enhancer of activated B cells), and thus induces an antioxidant and anti-inflammatory phenotype. Several lines of evidence suggest that Nrf2 activation can increase mitochondrial respiration and biogenesis. Collectively, available data suggest that the ability of RTA 408 to activate Nrf2 and induce its target genes could potentially improve muscle function, oxidative phosphorylation, antioxidant capacity, and mitochondrial biogenesis in patients with mitochondrial myopathies.

This study will be a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in patients with mitochondrial myopathies.

Full Title of Study: “A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: November 2, 2017

Interventions

  • Drug: Omaveloxolone capsules, 2.5 mg
  • Drug: omaveloxolone capsules, 5 mg
  • Drug: omaveloxolone capsules, 10 mg
  • Drug: Placebo capsules
  • Drug: omaveloxolone capsules, 20 mg
  • Drug: omaveloxolone capsules, 40 mg
  • Drug: omaveloxolone capsules, 80 mg
  • Drug: omaveloxolone capsules, 160 mg

Arms, Groups and Cohorts

  • Experimental: omaveloxolone Capsules 2.5 mg and 5 mg
    • omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
  • Experimental: omaveloxolone Capsules 10 mg
    • omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
  • Placebo Comparator: Placebo Capsules
    • Placebo capsules taken orally once daily for 12 weeks
  • Experimental: omaveloxolone Capsules 20 mg
    • omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
  • Experimental: omaveloxolone Capsules 40 mg
    • omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
  • Experimental: omaveloxolone Capsules 80 mg
    • omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
  • Experimental: omaveloxolone Capsules 160 mg
    • omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Change of Peak Workload (in Watts/kg) During Exercise Testing
    • Time Frame: 12 weeks
    • Cycle ergometry using a stationary recumbent bike was used to conduct maximal exercise testing. Peak work is defined as the workload at which patients reach maximal volition (defined as an inability to continue to exercise due to exhaustion).

Secondary Measures

  • Change in 6-minute Walk Test (6MWT) Distance
    • Time Frame: 6MWT was assessed at Week 4, Week 8, and Week 12 and compared to baseline
    • Patients were instructed to walk as far as they could along a marked path for 6 minutes. Distance walked was measured. If patients used a cane or walking assist device at Screening, the same walking assist device was to be used for all 6MWT assessments.

Participating in This Clinical Trial

Inclusion Criteria

1. Have mitochondrial myopathy as evidenced by the following 2 criteria (must meet both):

1. Have a history of exercise intolerance with or without weakness and/or progressive exercise intolerance (in which modest exercise typically provokes heaviness, weakness, aching of active muscles, or tachycardia)

2. Have a known primary mitochondrial DNA mutation or a nuclear DNA defect that is associated with reduced activity of at least 1 mitochondrially encoded respiratory chain complex

2. Be male or female and ≥18 years of age and ≤75 years of age

3. Have no changes to exercise regimen within 30 days prior to Study Day 1 and be willing to remain on the same exercise regimen during the 16-week study period

4. Have the ability to complete maximal exercise testing

5. Have a peak workload during maximal exercise testing of ≤ 1.5 W/kg

6. Be able to swallow capsules

Exclusion Criteria

1. Have uncontrolled diabetes (HbA1c >11.0%)

2. Have B-type natriuretic peptide level >200 pg/mL

3. Have a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease

4. Have known active fungal, bacterial, and/or viral infection, including human immunodeficiency virus or hepatitis virus (B or C)

5. Have known or suspected active drug or alcohol abuse

6. Have clinically significant abnormalities of clinical hematology or biochemistry, including but not limited to elevations greater than 1.5 times the upper limit of normal of aspartate aminotransferase, alanine aminotransferase, or creatinine

7. Have any abnormal laboratory test value or serious pre-existing medical condition that, in the opinion of the investigator, would put the patient at risk by study enrollment

8. Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to take any of these drugs during the time of study participation:

1. Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide, midazolam, sildenafil)

2. Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin)

9. Have participated in any other interventional clinical study within 30 days prior to Study Day 1

10. Have a cognitive impairment that may preclude ability to comply with study procedures

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Reata Pharmaceuticals, Inc.
  • Collaborator
    • AbbVie
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.